Found: 21
Select item for more details and to access through your institution.
Pooled Modeling of Disease Progression in Two BACE1 Inhibitor Verubecestat Trials in Prodromal to Moderate Alzheimer's Disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.082993
- By:
- Publication type:
- Article
P3‐040: VERUBECESTAT PHARMACOKINETIC AND EXPOSURE‐RESPONSE RESULTS FROM APECS, A PHASE 3 TRIAL IN PRODROMAL ALZHEIMER'S DISEASE.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P941, doi. 10.1016/j.jalz.2019.06.3066
- By:
- Publication type:
- Article
P2‐002: AN INTEGRATED MECHANISTIC AMYLOID PATHWAY MODEL INFORMED BY CLINICAL BIOMARKER DATA FROM VERUBECESTAT AND OTHER BACE INHIBITORS.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P571, doi. 10.1016/j.jalz.2019.06.1224
- By:
- Publication type:
- Article
P1‐044: VERUBECESTAT DISEASE PROGRESSION MODELING FROM APECS, A PHASE 3 TRIAL IN PRODROMAL ALZHEIMER'S DISEASE: NO DOSE‐ AND EXPOSURE‐DEPENDENCY IN CLINICAL ENDPOINTS.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P249, doi. 10.1016/j.jalz.2019.06.069
- By:
- Publication type:
- Article
P1‐038: VERUBECESTAT PHARMACOKINETIC AND EXPOSURE‐RESPONSE RESULTS FROM EPOCH: A PHASE 3 TRIAL IN MILD‐TO‐MODERATE ALZHEIMER'S DISEASE.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P281, doi. 10.1016/j.jalz.2018.06.039
- By:
- Publication type:
- Article
IS THE PERIPHERAL SINK HYPOTHESIS PHYSIOLOGICALLY FEASIBLE? EVIDENCE FROM MODEL-BASED ASSESSMENT OF THE AMYLOID PATHWAY.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016, v. 12, p. P443, doi. 10.1016/j.jalz.2016.06.855
- By:
- Publication type:
- Article
EVIDENCE FROM MODEL-BASED ASSESSMENTS OF COMPOUNDS TESTED IN COMPLETED CLINICAL TRIALS INDICATES THAT THE AMYLOID HYPOTHESIS HAS NOT BEEN ADEQUATELY TESTED.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016, v. 12, p. P609, doi. 10.1016/j.jalz.2016.06.1209
- By:
- Publication type:
- Article
Development and application of a mathematical model of modulation of cerebrospinal fluid Aβ40 after treatment with gamma- and beta-secretase inhibitors
- Published in:
- 2012
- By:
- Publication type:
- Abstract
An integrated mechanistic model to interrelate CSF Aβ40, Aβ42, sAPPβ and sAPPα response to β- and γ-secretase inhibitors in rhesus monkey
- Published in:
- 2012
- By:
- Publication type:
- Abstract
Population pharmacokinetic modeling of the novel BACE inhibitor MK-8931 following single and multiple dose administration in healthy subjects
- Published in:
- 2012
- By:
- Publication type:
- Abstract
Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Neuromyelitis Optica Spectrum Disorder.
- Published in:
- Frontiers in Neurology, 2021, v. 12, p. 1, doi. 10.3389/fneur.2021.696387
- By:
- Publication type:
- Article
Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis.
- Published in:
- Frontiers in Neurology, 2021, v. 12, p. 1, doi. 10.3389/fneur.2021.696385
- By:
- Publication type:
- Article
Early stage development of the glycine-1 re-uptake inhibitor SCH 900435: central nervous system effects compared with placebo in healthy men.
- Published in:
- British Journal of Clinical Pharmacology, 2013, v. 75, n. 6, p. 1455, doi. 10.1111/bcp.12015
- By:
- Publication type:
- Article
Model‐Informed Selection of the Recommended Phase III Dose of the Inhibitor of Apoptosis Protein Inhibitor, Xevinapant, in Combination with Cisplatin and Concurrent Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 1, p. 52, doi. 10.1002/cpt.3065
- By:
- Publication type:
- Article
Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2023, v. 12, n. 10, p. 1499, doi. 10.1002/psp4.13028
- By:
- Publication type:
- Article
Population pharmacokinetic analysis of sparsentan in healthy volunteers and patients with focal segmental glomerulosclerosis.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2023, v. 12, n. 8, p. 1080, doi. 10.1002/psp4.12996
- By:
- Publication type:
- Article
A time-to-event analysis of the exposure–response relationship for bezlotoxumab concentrations and CDI recurrence.
- Published in:
- Journal of Pharmacokinetics & Pharmacodynamics, 2020, v. 47, n. 2, p. 121, doi. 10.1007/s10928-019-09660-5
- By:
- Publication type:
- Article
Exposure–Response Analyses for Belzutifan to Inform Dosing Considerations and Labeling.
- Published in:
- Journal of Clinical Pharmacology, 2024, v. 64, n. 10, p. 1246, doi. 10.1002/jcph.2459
- By:
- Publication type:
- Article
Population PK Analyses of Ubrogepant (MK‐1602), a CGRP Receptor Antagonist: Enriching In‐Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling.
- Published in:
- Journal of Clinical Pharmacology, 2018, v. 58, n. 3, p. 294, doi. 10.1002/jcph.1021
- By:
- Publication type:
- Article
Population pharmacokinetic and exposure‐response analyses of ivosidenib in patients with IDH1‐mutant advanced hematologic malignancies.
- Published in:
- CTS: Clinical & Translational Science, 2021, v. 14, n. 3, p. 942, doi. 10.1111/cts.12959
- By:
- Publication type:
- Article
Making Better Dose Decisions: Using Exposure‐Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment.
- Published in:
- CTS: Clinical & Translational Science, 2020, v. 13, n. 3, p. 482, doi. 10.1111/cts.12730
- By:
- Publication type:
- Article